Opioid use disorders (prescription opioids and illicit opiates) Mental and Behavioural Disorders
Conditions
Interventions
Inpatient phase (4 weeks):
Participants using illicit opioid dependence will receive a 3-day BNX-F dose induction
those using prescription opioid use will receive a 5-day induction. This is followed by a 14-day dose stabilisation (patients allocated to daily, alternate day or thrice weekly dosing regimens) accord
Sponsors
National Rehabilitation Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Males and females aged 18- 64 years 2. Diagnosed with current opioid use disorder (ICD-10) 3. Current use of street heroin and/or pharmaceutical opioid 4. Able to comprehend instructions and consent to the trial participation 5. Voluntarily seeking treatment 6. Able to be discharged to stable accommodation
Exclusion criteria
Exclusion criteria: 1. Pregnant 2. Patients with known hypersensitivity to naloxone or buprenorphine 3. Hepatic Impairment (>3 times elevated liver function) 4. Any prior suicidal attempt and current active suicide plan 5. Involvement in current criminal justice proceedings 6. Active uncontrolled severe mental illness or evidence of organic brain disease that is judged by clinical director to compromise patient safety 7. Acute and severe respiratory illness 8. Paralytic ileus 9. Benzodiazepine use (in the past 28 days) in excess of 20 mg daily diazepam equivalent ,2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean % of UDS negative tests for opioid class. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean % of patients completing study period (retention) 2. Mean change in the following clinical parameters (depression, anxiety, impulsiveness, addiction severity index (ASI), work and social adjustment | — |
Countries
United Arab Emirates
Outcome results
None listed